Brezosiran Demonstrates Mutant Huntingtin Reduction in Phase 1b Huntington Disease Study

04 Nov 2026 0 comments

Alnylam Pharmaceuticals reported initial Phase 1b findings showing brezosiran reduced cerebrospinal fluid mutant huntingtin levels by a mean of 60% to 64% at 3 months, with plans for a pivotal study in 2027.

Source: NeurologyLive Published 03 Nov 2026 Imported 04 Nov 2026 Relevancy: Not reviewed

Read the article

Comments

No comments yet.

Unrestricted

All comments are reviewed before being published. Most comments are approved unless they are clearly inappropriate or unsafe.

Comments

Leave a comment